[Plasma concentrations of plasminogen activator inhibitor 2 in patients with hematological malignancies and their clinical significance].
We investigated plasma levels of plasminogen activator inhibitor 2 (PAI-2) in 40 patients with hematological malignancies including acute leukemia, chronic leukemia, hemophagocytic histiocytosis (HH) and histiocytic sarcoma (HS). The plasma PAI-2 levels in the patients with mononuclear phagocyte system (MPS) proliferative disorders (M4, M5, and CMMoL on FAB classification, HH and HS) were all above the cut-off value in healthy subjects. In a patient of reactive HH, there was a close correlation between Plasma PAI-2 and serum ferritin levels during the clinical course. These results indicate that the increase of plasma PAI-2 would be a diagnostic indicator of MPS proliferative disorders.
Shimmyozu
K
K
Division of Transfusion Medicine, Kagoshima University Hospital.
Machigashira
N
N
Itoyama
T
T
Tara
M
M
Maruyama
I
I
Osame
M
M
D000328:Adult; D005260:Female; D005293:Ferritins / Q000097:blood; D015616:Histiocytosis, Non-Langerhans-Cell / Q000175:diagnosis; D006801:Humans; D007938:Leukemia / Q000175:diagnosis*; D007945:Leukemia, Lymphoid / Q000175:diagnosis; D007951:Leukemia, Myeloid / Q000175:diagnosis; D008297:Male; D015849:Plasminogen Inactivators / Q000097:blood*; D011247:Pregnancy
D015849:Plasminogen Inactivators; D005293:Ferritins